Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CC-90001 in Idiopathic Pulmonary Fibrosis
NCT03142191Phase 2Terminated
- Sponsor
- Celgene Corporation
- Start
- Jul 2017
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 13
01
Overview
A Phase 2 trial of CC-90001 in idiopathic pulmonary fibrosis (IPF), pulmonary fibrosis (PF), sponsored by Celgene Corporation. Started Jul 2017; status: terminated.
02
Drugs
CC-90001
03
Conditions
idiopathic pulmonary fibrosis (IPF)pulmonary fibrosis (PF)
Beyond the preview
Go deeper on NCT03142191.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03142191.